Abstract:BACKGROUND:The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.METHODS:This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 centres in 13 countries. Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator. Randomisation, stratified by EGFR mutation type and status of brain metastases, was done centrally using a validated number generating system implemented via an interactive voice or web-based response system with a block size of four. Clinicians and patients were not masked to treatment allocation; independent review of tumour response was done in a blinded manner. Coprimary endpoints were progression-free survival by independent central review, time-to-treatment failure, and overall survival. Efficacy analyses were done in the intention-to-treat population and safety analyses were done in patients who received at least one dose of study drug. This ongoing study is registered with ClinicalTrials.gov, number NCT01466660.FINDINGS:Between Dec 13, 2011, and Aug 8, 2013, 319 patients were randomly assigned (160 to afatinib and 159 to gefitinib). Median follow-up was 27·3 months (IQR 15·3-33·9). Progression-free survival (median 11·0 months [95% CI 10·6-12·9] with afatinib vs 10·9 months [9·1-11·5] with gefitinib; hazard ratio [HR] 0·73 [95% CI 0·57-0·95], p=0·017) and time-to-treatment failure (median 13·7 months [95% CI 11·9-15·0] with afatinib vs 11·5 months [10·1-13·1] with gefitinib; HR 0·73 [95% CI 0·58-0·92], p=0·0073) were significantly longer with afatinib than with gefitinib. Overall survival data are not mature. The most common treatment-related grade 3 or 4 adverse events were diarrhoea (20 [13%] of 160 patients given afatinib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3%] of those given gefitinib) and liver enzyme elevations (no patients given afatinib vs 14 [9%] of those given gefitinib). Serious treatment-related adverse events occurred in 17 (11%) patients in the afatinib group and seven (4%) in the gefitinib group. Ten (6%) patients in each group discontinued treatment due to drug-related adverse events. 15 (9%) fatal adverse events occurred in the afatinib group and ten (6%) in the gefitinib group. All but one of these deaths were considered unrelated to treatment; one patient in the gefitinib group died from drug-related hepatic and renal failure.INTERPRETATION:Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile. These data are potentially important for clinical decision making in this patient population.FUNDING:Boehringer Ingelheim.

Afatinib in the treatment of EGFR mutation-positive NSCLC–a network meta-analysis

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

Comparative Outcome Assessment of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Advanced Non-Small-cell Lung Cancer: a Network Meta-Analysis.

A Bayesian Network Meta-Analysis of EGFR-tyrosine Kinase Inhibitor Treatments in Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-cell Lung Cancer Harboring EGFR Mutations.

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

P3.02b-081 Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis: Topic: EGFR Clinical

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial

The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

A Bayesian Network Comparison of Different Agents or Regimens As First-Line Treatment for Advanced EGFR-mutated NSCLC.

Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: A network meta-analysis

Afatinib in the Treatment of Advanced NSCLC with EGFR Mutation: an Observational Real-World Study.

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis

Comparison Of Gefitinib, Erlotinib And Afatinib In Non-Small Cell Lung Cancer: A Meta-Analysis

Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence.

Therapeutic Efficacy Comparison of 5 Major Egfr-Tkis in Advanced Egfr-Positive Non-Small-Cell Lung Cancer: A Network Meta-Analysis Based on Head-To-Head Trials

Afatinib Versus Gefitinib As First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-cell Lung Cancer (Lux-Lung 7): a Phase 2B, Open-Label, Randomised Controlled Trial